This is also important in the context of the effects of ruxolitinib, which produces a more profound inhibition of STAT phosphorylation (Fig 3F), but for which thrombocytopaenia, and to a lesser extent anaemia and susceptibility to infection, are significant side effects [11,38]. Here, SOAT1 is linked to infection.